PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer

Basit Öğe Kaydı
dc.authoridokcu, oguzhan/0000-0001-7481-4718
dc.authoridBenek, Suat/0000-0003-0774-7695
dc.contributor.authorZengin, Mehmet
dc.contributor.authorZergeroglu, Sema
dc.contributor.authorOkcu, Oguzhan
dc.contributor.authorBenek, Suat
dc.date.accessioned2025-01-21T16:43:19Z
dc.date.available2025-01-21T16:43:19Z
dc.date.issued2021
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated. Methods Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors. Results We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS. Conclusions Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted theapies.
dc.description.sponsorshipScientific Research Projects Coordination Unit of Kirikkale University
dc.description.sponsorshipThis work was supported by the Scientific Research Projects Coordination Unit of Kirikkale University.
dc.identifier.doi10.1007/s13402-020-00579-5
dc.identifier.endpage432
dc.identifier.issn2211-3428
dc.identifier.issn2211-3436
dc.identifier.issue2
dc.identifier.pmid33469839
dc.identifier.scopus2-s2.0-85100021704
dc.identifier.scopusqualityQ1
dc.identifier.startpage423
dc.identifier.urihttps://doi.org/10.1007/s13402-020-00579-5
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25242
dc.identifier.volume44
dc.identifier.wosWOS:000608965100003
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofCellular Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241229
dc.subjectColorectal cancer; PD-1; PDL-2; Prognostic biomarkers; Stage III
dc.titlePD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu